Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± BMS-986205 with or without intravesical BCG in high-risk BCG-unresponsive NMIBC
CTR20181558Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, linrodostat in bladder cancer, sponsored by Bristol Myers Squibb. Started Jul 2019; status: terminated.
02
Drugs
nivolumablinrodostat
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20181558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181558.